First-trimester risk stratification and low-dose aspirin prophylaxis decision
Preeclampsia complicates roughly 3–8% of pregnancies worldwide and remains a leading cause of maternal and perinatal morbidity and mortality. Because effective prophylaxis exists, professional societies recommend universal first-trimester screening using a structured checklist of clinical risk factors to identify candidates for low-dose aspirin before the disease process begins.
A single high-risk factor is sufficient on its own to recommend aspirin prophylaxis. These include: a history of preeclampsia in a prior pregnancy (especially if early-onset or severe — recurrence risk 15–20%), chronic hypertension, pregestational (type 1 or 2) diabetes mellitus, chronic kidney disease, autoimmune disease with antiphospholipid syndrome or systemic lupus erythematosus, and multifetal gestation (twins or higher-order).
Each of these conditions shares a common pathway: they impair the normal vascular and immunologic adaptations of early placentation, predisposing to the shallow trophoblast invasion that underlies preeclampsia.
Patients with any high-risk factor should be counseled and started on aspirin regardless of any other clinical variable — no further risk stratification is required to make the treatment decision.
Moderate-risk factors each confer a smaller independent increment in risk, and current USPSTF/ACOG guidance recommends aspirin when two or more are present. These include: nulliparity, obesity (BMI ≥30), family history of preeclampsia (mother or sister), maternal age ≥35 years, prior adverse pregnancy outcome (low birth weight, placental abruption, fetal death), an interpregnancy interval of more than 10 years, and conception via assisted reproductive technology (IVF).
Sociodemographic factors — Black race (as a marker of structural racism and its physiologic sequelae rather than biological race itself) and low socioeconomic status — are also incorporated in some algorithms given their independent association with adverse pregnancy outcomes.
Because moderate factors are common (nulliparity alone affects roughly 40% of pregnancies), requiring two or more before recommending aspirin balances sensitivity against unnecessary medication exposure in a large population.
Screening should occur at the first prenatal visit, ideally in the late first trimester (before 16 weeks), because the therapeutic window for aspirin to meaningfully alter placental development closes as gestation advances. A structured checklist — rather than unstructured clinical gestalt — improves consistency and sensitivity, and is now built into most prenatal intake forms and electronic health record templates.
Simple checklist-based screening (ACOG/USPSTF approach, using history alone) achieves a detection rate for preterm preeclampsia of roughly 90% at a screen-positive rate of about 10%, without requiring any additional testing — making it feasible for universal application in any prenatal care setting, including resource-limited environments.
Because a single high-risk factor is sufficient to trigger aspirin prophylaxis, screening can and should begin at the very first prenatal contact — delaying the decision until later visits erodes the drug's effectiveness, since benefit is greatest when initiation occurs before 16 weeks.
For patients with borderline or uncertain risk by history alone, first-trimester uterine artery Doppler velocimetry and maternal serum placental growth factor (PlGF) provide direct physiologic evidence of placental vascular resistance, substantially improving risk discrimination when combined with maternal characteristics in algorithms such as the Fetal Medicine Foundation (FMF) competing-risks model.
In normal pregnancy, trophoblast invasion of the maternal spiral arteries converts them from high-resistance, muscular vessels into low-resistance, flaccid conduits capable of delivering the roughly 10-fold increase in uteroplacental blood flow required by term. This remodeling is reflected in the uterine artery Doppler waveform, which normally shows progressively falling resistance (falling pulsatility index, disappearance of the early diastolic notch) as gestation advances.
In pregnancies destined for preeclampsia, incomplete trophoblast invasion leaves the spiral arteries narrow and muscular, producing persistently high resistance: an elevated pulsatility index (PI above the 95th percentile for gestational age) and a persistent bilateral diastolic notch on the waveform — a direct sonographic signature of the underlying placental pathology.
UtA Doppler is measured transabdominally or transvaginally at 11–13+6 weeks, averaging the PI from both uterine arteries.
Placental growth factor (PlGF), a pro-angiogenic protein produced by the placenta, is characteristically reduced in pregnancies destined to develop preeclampsia, reflecting impaired placental vascular development. Conversely, soluble fms-like tyrosine kinase-1 (sFlt-1), an anti-angiogenic protein that antagonizes PlGF and VEGF signaling, rises — the sFlt-1/PlGF ratio is now used clinically (particularly in Europe) both for risk prediction and, later in pregnancy, to rule out imminent preeclampsia in symptomatic patients with high negative predictive value.
In first-trimester combined screening, low PlGF adds independent predictive value to maternal risk factors and UtA Doppler, and its incorporation is central to the FMF competing-risks algorithm, which outputs a patient-specific risk for preterm preeclampsia rather than a binary risk category.
The FMF algorithm combines maternal factors (age, BMI, parity, medical history, ethnicity), mean arterial pressure, UtA Doppler PI, and PlGF (± PAPP-A) into a single patient-specific risk estimate for preterm preeclampsia, achieving detection rates of roughly 75–90% at a fixed 10% screen-positive rate — substantially outperforming maternal-history-only screening (roughly 40–50% detection at the same false-positive rate).
Despite superior performance, combined biomarker screening is not universally implemented because it requires specialized equipment, sonographer training for standardized UtA Doppler, and biomarker assay availability — resources not present in every prenatal care setting. Consequently, both the simple checklist approach (ACOG/USPSTF) and the combined algorithm (FMF, adopted more widely in the UK and Europe) remain in concurrent clinical use, with the checklist approach dominating in the United States.
Whichever algorithm is used, the clinical action for a screen-positive result is the same: initiate low-dose aspirin before 16 weeks. Combined biomarker screening improves who gets flagged, but does not change what is offered once flagged.
Low-dose aspirin is the single most effective, evidence-based intervention available to reduce preterm preeclampsia risk. Its benefit is highly time-sensitive: aspirin acts by modulating early placental prostaglandin balance during the window of trophoblast invasion, so initiation after roughly 16 weeks — once spiral artery remodeling is largely complete — yields substantially less benefit.
Low-dose aspirin irreversibly acetylates cyclooxygenase-1 (COX-1) in platelets, suppressing thromboxane A2 (a potent vasoconstrictor and platelet aggregant) production for the lifespan of the platelet (7–10 days), while sparing endothelial prostacyclin (a vasodilator) production at low doses because nucleated endothelial cells can resynthesize COX enzyme.
This selective shift in the thromboxane/prostacyclin balance toward vasodilation and away from platelet aggregation is thought to improve trophoblast invasion and spiral artery remodeling during the critical window of placentation (weeks 8–16), reducing the downstream cascade of endothelial dysfunction that produces clinical preeclampsia.
Because the mechanism operates on placental development itself rather than treating established disease, aspirin's benefit is concentrated in preventing preterm (<37 week) preeclampsia, with a much smaller effect on term disease, which likely has a different, less placentally-driven pathophysiology.
The landmark ASPRE trial (Rolnick et al., NEJM 2017) randomized over 1,700 women at high risk for preterm preeclampsia (identified by the FMF combined first-trimester screening algorithm) to aspirin 150mg nightly versus placebo, started between 11 and 14 weeks and continued until 36 weeks. Aspirin reduced preterm preeclampsia (<37 weeks) by approximately 62%, with the greatest benefit for the earliest and most severe disease.
Subsequent meta-analyses support a dose-response relationship: doses ≥100mg appear more effective than lower doses (e.g., 60–81mg used in some earlier trials), leading current guidance to favor doses at the higher end of the approved range (81–162mg, commonly 81mg in the US given available formulations, though some experts now favor 162mg — two 81mg tablets — for higher-risk patients).
Timing of dosing (morning versus evening) has been debated, but the dominant driver of efficacy is early initiation and consistent daily adherence rather than time of day.
The ASPRE trial's 62% reduction in preterm preeclampsia is among the largest effect sizes of any obstetric preventive intervention — comparable in magnitude to the benefit of antenatal corticosteroids for reducing neonatal respiratory distress syndrome.
Low-dose aspirin has an excellent maternal and fetal safety profile at the doses used for preeclampsia prophylaxis: it does not increase risk of placental abruption, postpartum hemorrhage, or neonatal bleeding complications, and is not associated with premature closure of the fetal ductus arteriosus at these low doses (unlike higher-dose NSAIDs used for tocolysis).
Aspirin should be continued through delivery (typically discontinued at 36 weeks or continued to delivery per local protocol) rather than stopped early, since the placental vascular benefit requires sustained exposure across the second and third trimesters.
Adherence is the most common practical barrier — patients should be counseled explicitly that aspirin is being used for a different indication (placental vascular health) than its common association with pain relief or cardiac prophylaxis, and that missing doses meaningfully reduces the accumulated benefit. Aspirin does not eliminate preeclampsia risk; ongoing blood pressure and symptom surveillance remains mandatory regardless of prophylaxis.
Aspirin prophylaxis reduces but does not eliminate preeclampsia risk, and term preeclampsia in particular is less well prevented by aspirin than preterm disease. Every at-risk patient — whether or not on aspirin — requires structured ongoing surveillance for the clinical signs of preeclampsia throughout the second and third trimesters, with a clear escalation pathway toward magnesium sulfate seizure prophylaxis if severe features develop.
Every prenatal visit for an at-risk patient should include blood pressure measurement using proper technique (seated, arm at heart level, appropriate cuff size, repeat if elevated) and a structured symptom review: severe or persistent headache unresponsive to acetaminophen, visual disturbances (scotomata, blurred vision), right upper quadrant or epigastric pain, and sudden edema or rapid weight gain.
Urine protein screening (spot protein/creatinine ratio, or 24-hour urine collection if borderline) is obtained when blood pressure is elevated or symptoms are present; routine urine dipstick at every visit has largely been de-emphasized in favor of targeted testing given poor sensitivity/specificity of dipstick alone.
Fetal surveillance (growth ultrasounds, and antenatal testing such as nonstress tests or biophysical profiles in the third trimester) is added for high-risk patients because preeclampsia frequently coexists with placental insufficiency and fetal growth restriction.
Preeclampsia is diagnosed by new-onset hypertension (systolic ≥140 or diastolic ≥90 mmHg on two occasions at least 4 hours apart) after 20 weeks gestation, plus either proteinuria (≥300mg/24h, protein/creatinine ratio ≥0.3, or dipstick 2+ in the absence of other quantitative testing) or, in the absence of proteinuria, evidence of maternal end-organ dysfunction (thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, or new-onset headache/visual symptoms).
Severe features — severe-range blood pressure (≥160 systolic or ≥110 diastolic, confirmed), thrombocytopenia (<100,000/µL), liver transaminases twice the upper limit of normal, renal insufficiency (creatinine >1.1mg/dL or doubling), pulmonary edema, or new cerebral/visual symptoms — mark the transition point at which delivery is usually indicated regardless of gestational age (with brief latency for corticosteroids if remote from term and maternal/fetal status allows).
For patients who progress to preeclampsia with severe features, magnesium sulfate is administered for seizure (eclampsia) prophylaxis — typically a 4–6g IV loading dose followed by a 1–2g/hour maintenance infusion, continued through delivery and for 24 hours postpartum. Magnesium reduces the risk of eclamptic seizure by roughly half compared with no prophylaxis, and is one of the best-studied interventions in obstetrics (Magpie trial).
Magnesium toxicity is monitored clinically (deep tendon reflexes, respiratory rate, urine output) since it is renally cleared and accumulates in renal impairment; calcium gluconate is the antidote for magnesium toxicity (loss of reflexes, respiratory depression).
This represents the downstream endpoint that first-trimester risk stratification and aspirin prophylaxis are designed to prevent — successful early identification and treatment reduces, but does not eliminate, the number of patients who ultimately require this acute severe-disease management pathway.
The entire preeclampsia prevention pathway — risk screening, Doppler/biomarker refinement, and aspirin prophylaxis — exists to reduce the number of patients who ever reach the magnesium sulfate / severe-disease endpoint. Prevention and acute management are two ends of the same clinical continuum.